Lantheus' Pylarify Hit $1B in 2024 Sales
Lantheus Holdings (NASDAQ: LNTH) held its fourth-quarter and full-year 2024 earnings call on Feb. 26, 2025, highlighting achievements in its radiopharmaceutical portfolio and announcing strategic transactions.Prostate imaging drug Pylarify has become the first radiodiagnostic blockbuster, achieving over $1 billion in sales for 2024. The addressable market continues to expand.We estimate [the addressable market] to be $2.5-plus billion in 2025 up from $2-plus billion in 2024, while the total addressable market could exceed $3.5 billion by the end of the decade.-- Paul Blanchfield, PresidentContinue reading
Lantheus Holdings (NASDAQ: LNTH) held its fourth-quarter and full-year 2024 earnings call on Feb. 26, 2025, highlighting achievements in its radiopharmaceutical portfolio and announcing strategic transactions.
Prostate imaging drug Pylarify has become the first radiodiagnostic blockbuster, achieving over $1 billion in sales for 2024. The addressable market continues to expand.
We estimate [the addressable market] to be $2.5-plus billion in 2025 up from $2-plus billion in 2024, while the total addressable market could exceed $3.5 billion by the end of the decade.
-- Paul Blanchfield, President
